Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers

Cancers (Basel). 2020 Sep 27;12(10):2768. doi: 10.3390/cancers12102768.

Abstract

Bladder cancer and renal cell carcinoma (RCC) are the second and third most commonly diagnosed cancers in the field of uro-oncology [...].

Publication types

  • Editorial